Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

234 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry.
Xu X, Veenstra TD, Fox SD, Roman JM, Issaq HJ, Falk R, Saavedra JE, Keefer LK, Ziegler RG. Xu X, et al. Anal Chem. 2005 Oct 15;77(20):6646-54. doi: 10.1021/ac050697c. Anal Chem. 2005. PMID: 16223252
Hepatoselective Nitric Oxide (NO) Donors, V-PYRRO/NO and V-PROLI/NO, in Nonalcoholic Fatty Liver Disease: A Comparison of Antisteatotic Effects with the Biotransformation and Pharmacokinetics.
Kus K, Walczak M, Maslak E, Zakrzewska A, Gonciarz-Dytman A, Zabielski P, Sitek B, Wandzel K, Kij A, Chabowski A, Holland RJ, Saavedra JE, Keefer LK, Chlopicki S. Kus K, et al. Among authors: keefer lk. Drug Metab Dispos. 2015 Jul;43(7):1028-36. doi: 10.1124/dmd.115.063388. Epub 2015 Apr 13. Drug Metab Dispos. 2015. PMID: 25870102
Injectable formulation of disodium 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO), an ultrafast nitric oxide donor prodrug.
Waterhouse DJ, Saavedra JE, Davies KM, Citro ML, Xu X, Powell DA, Grimes GJ, Potti GK, Keefer LK. Waterhouse DJ, et al. J Pharm Sci. 2006 Jan;95(1):108-15. doi: 10.1002/jps.20486. J Pharm Sci. 2006. PMID: 16315224
Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound.
Chakrapani H, Wilde TC, Citro ML, Goodblatt MM, Keefer LK, Saavedra JE. Chakrapani H, et al. Bioorg Med Chem. 2008 Mar 1;16(5):2657-64. doi: 10.1016/j.bmc.2007.11.035. Epub 2007 Nov 17. Bioorg Med Chem. 2008. PMID: 18060792 Free PMC article.
Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
Maciag AE, Nandurdikar RS, Hong SY, Chakrapani H, Diwan B, Morris NL, Shami PJ, Shiao YH, Anderson LM, Keefer LK, Saavedra JE. Maciag AE, et al. J Med Chem. 2011 Nov 24;54(22):7751-8. doi: 10.1021/jm2004128. Epub 2011 Oct 28. J Med Chem. 2011. PMID: 22003962 Free PMC article.
Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: requirement for Cyp1a1.
Qu W, Cheng L, Dill AL, Saavedra JE, Hong SY, Keefer LK, Waalkes MP. Qu W, et al. Chem Biol Interact. 2011 Aug 15;193(1):88-96. doi: 10.1016/j.cbi.2011.05.005. Epub 2011 May 20. Chem Biol Interact. 2011. PMID: 21621526 Free PMC article.
V-PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenic-induced toxicity.
Qu W, Liu J, Dill AL, Saavedra JE, Keefer LK, Waalkes MP. Qu W, et al. Cancer Sci. 2009 Mar;100(3):382-8. doi: 10.1111/j.1349-7006.2008.01050.x. Epub 2008 Dec 15. Cancer Sci. 2009. PMID: 19154403 Free PMC article.
V-PROLI/NO, a prodrug of the nitric oxide donor, PROLI/NO.
Chakrapani H, Showalter BM, Kong L, Keefer LK, Saavedra JE. Chakrapani H, et al. Org Lett. 2007 Aug 16;9(17):3409-12. doi: 10.1021/ol701419a. Epub 2007 Jul 20. Org Lett. 2007. PMID: 17658755
234 results
Jump to page
Feedback